HENDERSON, Nev., Jan. 30, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the results of a large-scale study which shows that its Nu.Q®NETs H3.1 biomarker is an independent predictor of 28-day mortality and need for renal replacement therapy (RRT) in sepsis and septic shock patients.Findings published in the paper currently undergoing peer review and accessible on MEDRXIV, demonstrate Nu.Q® NETs H3.1 is a promising novel bioma ...

HENDERSON, Nev., Jan. 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, has issued a Business Review of 2024, outlining its key highlights from the past year. Volition's major achievements in 2024 include: Expanded access to the Nu.Q® Vet Cancer Test – now available for purchase in 20 countries worldwide. Sold over 110,000 Nu.Q® Vet Cancer Tests in the first three quarters 2024. Hosted Satellite Symposium at European Societ ...

Volition to participate in the upcoming 14th Annual LifeSci Partners Corporate Access Event on January 15th, 2025 at the Beacon Grand Hotel in San Francisco.HENDERSON, Nev., Dec. 12, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced that it has retained LifeSci Advisors, LLC ("LSA") a premiere life sciences corporate and financial communications agency, to provide investor relations advisory services.Cameron Reynolds, ...

Financial Data and Key Metrics - Revenue for the first nine months of 2024 reached $1 million, a 96% increase compared to the same period in 2023 [34] - Q3 2024 revenue grew by 187% year-on-year, reaching $475,000, driven by Nu Q Vet cancer test sales [34] - Nu Q Vet cancer test sales grew by 100% year-to-date and 307% in Q3 2024 compared to 2023 [34] - Over 110,000 Nu Q Vet cancer tests were sold in the first three quarters of 2024, nearly double the total sold in 2023 [8][34] - Operating expenses decreased by 28% in Q3 2024 compared to the same quarter in 2023 [35] - Cash used in operating activities was $5 4 million in Q3 2024, down 36% year-on-year [35] - Cash and cash equivalents at the end of Q3 2024 totaled approximately $5 4 million [36] Business Line Data and Key Metrics - Nu Q Vet cancer test is now available in 17 countries, with revenue growth accelerating quarter-on-quarter [10] - Year-to-date revenue growth for Nu Q Vet is 100%, with Q3 revenue up 307% compared to 2023 [10] - Revenue from veterinary kits and key components reached approximately $730,000 year-to-date [10] - Fujifilm Vet Systems achieved nearly 10% market penetration among veterinarians in Japan within a quarter of launching Nu Q Vet [11] - VetLab Poland and Heska (under Antech) have also made significant progress in distributing Nu Q Vet in their respective markets [12][13] Market Data and Key Metrics - Nu Q Vet is now available in 15 countries through Antech's distribution channels [13] - Japan represents a significant market for Nu Q Vet, with Fujifilm Vet Systems achieving rapid market penetration [11][45] - The U S market for Nu Q Vet is estimated at 25 million dogs, with a global opportunity of a similar size [48] Company Strategy and Industry Competition - The company aims to be cash-neutral by 2025, with significant progress made toward this goal through revenue growth and cost reduction [33][37] - The focus is on securing licensing deals in the human clinical space, with strong interest from key industry players in sepsis and oncology liquid biopsy [38][39] - The company is leveraging its success in veterinary diagnostics to commercialize human-focused technologies, including Nu Q NETs and Nu Q Cancer [40][41] - Non-dilutive funding from the Walloon Region, Belgium, and anticipated future funding support the company's financial strategy [36][37] Management Commentary on Operating Environment and Future Outlook - Management highlighted the strong progress in revenue growth and cost reduction, positioning the company well for cash neutrality in 2025 [33][37] - The company is optimistic about the potential for licensing deals in the human space, which could provide significant milestone payments and ongoing revenue [40][51] - The Nu Q NETs test for sepsis has generated significant interest, with potential to be a game-changer in sepsis management [28][31] - The company is exploring opportunities to include Nu Q Cancer tests in national lung cancer screening programs, particularly in Taiwan and other Asian markets [21][51] Other Important Information - The company welcomed new board members, Timothy Still and Dr Ethel Rubin, who bring extensive experience in the diagnostics sector [42] - The company is actively publishing scientific papers and presenting at conferences to strengthen its data room and support licensing discussions [30][31] - The feline testing milestone for Nu Q Vet is still in progress, with ongoing optimization for lower nucleosome levels in cats [78][80] Q&A Session Summary Question: Market dynamics and penetration in Japan - Fujifilm Vet Systems has achieved nearly 10% penetration among veterinarians in Japan, with strong marketing and distribution efforts [44][45] - Japan is a significant market, comparable to a large U S state like California, with high spending on pet care [45] Question: Revenue guidance and growth potential - Revenue growth is strong but can be lumpy due to the nature of distributor stocking and sell-through [47][63] - The company expects to ramp up to millions of tests annually, with a target market of 25 million dogs in the U S and a similar opportunity globally [48][49] Question: Cash neutrality and business segment self-sufficiency - The goal is for each business pillar to support itself through revenue and licensing deals, with significant progress made toward cash neutrality [54][55] - Licensing deals in the human space are expected to contribute to cash flow neutrality in 2025 [55][56] Question: Cost reduction progress - Operating expenses have been reduced by 28% in Q3 2024, with further reductions expected [57][58] - Approximately half of the $10 million cost-cutting program has been implemented, with full savings expected in 2025 [68][69] Question: Feline testing progress - Feline testing is still in development, with optimization for lower nucleosome levels in cats nearing completion [78][80] - Clinical utility studies for feline testing are expected to follow once the technical challenges are resolved [80] Question: Data rooms and licensing discussions - The company is using ShareVault to track data room activity, with significant interest from large diagnostic and oncology players [72][74] - Licensing discussions are progressing well, with potential for milestone payments and ongoing revenue from human-focused deals [74][75] Question: Upcoming data publications and presentations - Two large publications on sepsis are expected to be submitted by the end of Q4 2024 and early Q1 2025 [83] - Additional papers on oncology, particularly lung cancer, are also in progress [85]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-36833 VOLITIONRX LIMITED (Exact name of registrant as specified in its charter) | --- | |-------------------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission (IRS Employer of Incorporation) File Number) Identification Number) Title of Each Class Trading Symbol(s) Name of Each Exchange on which Registered Common Stock,par value $0.001 per share VNRX NYSE American, LLC FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, ...

Conference call to discuss financial and operational results scheduled forFriday, November 15 at 8:30 a.m. U.S. Eastern TimeHENDERSON, Nev.  , Nov. 14, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the third quarter of 2024. Volition management will host a conference call tomorrow, November 15 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be f ...

Conference call to take place on Friday, November 15 at 8:30 a.m. U.S Eastern TimeHENDERSON, Nev., Nov. 8, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announces that it will host a conference call on Friday, November 15 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the third quarter 2024, in addition to providing a business update. Details of this event can be found below.Event: VolitionRx Limited Third Quarter 2024 Earnings and Busine ...

HENDERSON, Nev., Nov. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Timothy Still as Chairman of its board of directors, effective November 06, 2024. Timothy Still, Chairman of Volition Mr. Still is currently Chairman and CEO of TSTILL Enterprises LLC, and an Operating Partner with REVIVAL Healthcare. An accomplished executive with a career spanning over 35 years in medical diagnostics, devices and digital health, his ...

HENDERSON, Nev., Oct. 31, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has published a report, from its 'NETs in sepsis management' symposium at ESICM Lives 2024 last month, which concluded that Nu.Q® NETs could be used to predict patients at greater risk of deteriorating from sepsis.The symposium explored research findings from three large, independent studies carried out at centers of excellence in France, Germany, and the Netherlands, i ...